# Viewpoint Round 1 — Editorial-Policy Reviewer Report

- **Round.** 1
- **Reviewer.** policy (Editorial-Policy Reviewer)
- **Date.** 2026-05-21
- **Manuscript commit.** `c694f073ba1d802541718b8449cad02698d9b4cd`
- **Target journal.** *The Lancet Digital Health*, article type Viewpoint
- **Model.** Anthropic Claude Opus 4.7 (1M-context variant), Claude Code dispatch

## Sources consulted

- `manuscript/main.tex` (the Viewpoint)
- `manuscript/references.bib`
- `manuscript/JOURNAL.md`
- `manuscript/cover-letter.md`
- `docs/ai-usage-disclosure.md`
- `docs/design.md`
- The Lancet group editorial-policies page, `https://www.thelancet.com/editorial-policies` (live page returned HTTP 403 from the reviewer's IP on 2026-05-21; the policy text was reconstructed from authoritative secondary sources that quote it verbatim, listed below)
- AMEE Guide No.192 on AI disclosure in academic publishing, Tandfonline 2025, `https://www.tandfonline.com/doi/full/10.1080/0142159X.2025.2607513` (HTTP 403 from this IP; quoted via the CSE Science Editor article)
- *Defining the Boundaries of AI Use in Scientific Writing*, PMC12170296, `https://pmc.ncbi.nlm.nih.gov/articles/PMC12170296/`
- *Lancet AI Policy: What's Allowed and Required (2026)*, Manusights, `https://manusights.com/blog/lancet-ai-policy` (dated 2026-03-24, updated 2026-04-02)
- *Assessing AI Policies in Scientific Publishing*, CSE Science Editor, `https://www.csescienceeditor.org/article/assessing-ai-policies-in-scientific-publishing/`
- *AI policies in academic publishing 2025*, Thesify, `https://www.thesify.ai/blog/ai-policies-academic-publishing-2025`

The reviewer flags that the operator should re-fetch `https://www.thelancet.com/editorial-policies` from an IP the Lancet site does not block and either confirm or correct every verbatim policy quotation reproduced below before submission. Policy text changes; the manuscript stakes its argument on it.

## Overall impression

The Viewpoint is publishable in some form and has a genuinely original thesis: that the 2026 disclosure unit must become `{prompt, model, tool envelope, commit history, reviewer transcripts, audit log, tagged release}` rather than a single methods-paragraph acknowledgement. The supporting "we ourselves were produced under this standard" demonstration is the strongest move in the piece and would be very difficult to deploy convincingly without exactly the repository the operator has built.

The Viewpoint nevertheless mis-quotes or under-quotes the current Lancet group policy at three load-bearing points and is silent on a fourth provision that materially changes Section 6's recommendation. None of these are fatal; all three would be raised at desk triage by a Lancet group editor and would either trigger a Major Revisions decision or, more likely, a desk return for "please verify your claims about our policy." The Viewpoint must quote the Lancet policy literally where it disagrees with it; sympathetic paraphrase, where the policy is the subject matter, is itself a category of the problem the Viewpoint diagnoses.

The implementability of the six-item Disclosure 2.0 manifest is adequately motivated for an opinion piece but is not pilot-ready; Editorial Manager does not accept arbitrary GitHub-linked manifests today, and the Viewpoint does not say what a 90-day pilot would look like. The equity dimension (submitters without git fluency) is absent. The symmetry argument is internally consistent but rests on a Lancet provision (reviewers may not use AI) that the manuscript does not name.

My verdict is **major-revision**. The core argument is strong enough to be a *Lancet Digital Health* Viewpoint; the policy-text accuracy and the implementability path need a focused rewrite before the next round.

---

## Numbered comments

### Comment 1 — `blocker` — Policy-text mis-quotation, multiple

The Viewpoint's argument turns on a contrast between "what the Lancet group's current generative-AI policy permits" and what Disclosure 2.0 would permit. The contrast is misstated in three places.

**1a. Permitted-uses scope.** Section 1 of the Viewpoint paraphrases Lancet permitted uses as "language editing, grammar repair and prose polishing". The Lancet group's currently published wording, as reproduced by Manusights 2026-03-24 quoting the live policy, is the narrower phrase **"readability and language improvements only"** (with "improve your English, fix grammar, restructure sentences for clarity, and polish prose" as illustrative examples). The Viewpoint paraphrase is close but not literal and treats illustration as scope.

**1b. Prohibited-uses scope.** Section 1 and `JOURNAL.md` list the prohibited uses as "generating scientific arguments, drafting methodology descriptions, producing literature reviews, creating new scientific content, generating images or figures". The published policy wording is **"can't use them to generate scientific arguments, draft methodology descriptions, write literature reviews, or create new content"** (Manusights 2026) — *"write"* not *"producing"*, *"new content"* not *"new scientific content"*. Image generation is prohibited under a **separate** Lancet provision ("No images from generative AI tools in any part of the manuscript"; *Lancet Global Health* 2024 editorial calls for science to "stop using AI-generated imagery"), not under the same sentence. Collapsing them into one prohibited-uses list is a category error that an editor will notice.

**1c. Disclosure location.** `JOURNAL.md` lines 87-95 claim disclosure must appear in **two** places — Methods section *and* Acknowledgements. The live Lancet group rule, per Manusights 2026, is a **single-location** rule: **"Disclosure goes in the acknowledgments"**, distinguished from *Science*'s three-location rule. The author's compliance plan is therefore over-specified relative to what the Lancet policy requires; this is not harmful for the submission, but the Viewpoint argues *against* the policy and must therefore quote it correctly. The AMEE Guide No.192 (Tandfonline 2025) does report a richer Lancet requirement that disclosure include "the model, the version, the prompt used, and the specific sections where it was applied"; the operator should reconcile these two characterisations against the live page on submission day.

**Why this is a blocker.** A Viewpoint whose central recommendation is "be more granular about AI disclosure" cannot itself be loose about quoting the policy it wants to revise. An editor will reject the manuscript at desk triage on this ground alone. The repair is small (quote literally, attribute to the live page with a retrieval date, and cite Lancet group editorials separately) but it must be made.

### Comment 2 — `high` — Section 6 omits the Lancet's reviewer-AI prohibition, weakening the symmetry argument

Section 6 of the Viewpoint argues: "*Permit reviewer subagents on the operator's side, subject to the same disclosure rules.* … symmetric disclosure is a necessary condition for any future editor-side reviewer-AI deployment."

The argument is internally consistent and is the most interesting normative move in the piece. But the Viewpoint does not engage with the actual Lancet group rule on the editor side: the published Lancet group policy is that **"reviewers should refrain from using generative AI or AI-assisted technologies to assist in the scientific review of papers"** (the CSE Science Editor 2025 review of journal policies; corroborated by the Manusights 2026 piece on the same page). That is, the editor-side reviewer-AI deployment to which Section 6 proposes a symmetric author-side regime is currently **prohibited by Lancet policy, not a near-future pilot.**

The symmetry argument is therefore stronger than the manuscript currently states (the asymmetry the manuscript proposes to fix is in the wrong direction — the current policy permits author-side AI in *neither* role and prohibits reviewer-side AI; the manuscript implicitly assumes the editor side is the more permissive one), and it is weaker in implementation (Section 6's recommendation that *author-side* reviewer-AI be permitted as long as it is disclosed is currently a one-sided ask, because no editor-side counterpart exists to be symmetric with). The Viewpoint must (i) quote the reviewer-AI prohibition explicitly, (ii) acknowledge that "symmetry" today means *both sides prohibited*, and (iii) reframe its proposal as "lift the asymmetric author-side prohibition, then re-evaluate the editor-side prohibition under the same disclosure regime" rather than as if both sides were already symmetric.

This omission is not in itself dishonest — the Viewpoint nowhere claims the editor-side use is permitted — but its absence makes the symmetry argument appear naive and is the second editorial objection the desk will raise.

### Comment 3 — `high` — Implementability: the six-item manifest has no Editorial Manager deployment path

The Viewpoint recommends (Section 6) "a small, schemafied YAML or JSON document committed at the repository root and validated at submission time by Editorial Manager or its successor." The operator points to `docs/disclosure2-schema.json` as a reference schema. There are two problems an editorial-policy reviewer must raise.

**3a. The schema is not in the repository as submitted.** I searched for `disclosure2-schema.json` under `docs/` and it is not present (only `ai-usage-disclosure.md`, `design.md`, `prereg.md` are there). The Viewpoint asserts the existence of an artefact that does not exist at the cited path. Either commit the schema before submission or remove the claim. The "the medium is the message" framing of the entire Viewpoint depends on the artefact being where the manuscript says it is; this is the second piece of artefact-drift the policy reviewer found (the first is comment 5 below on `reviewer-logs/round-01/methods.md`).

**3b. Editorial Manager has no current hook for repository-linked manifests.** The Viewpoint argues the manifest "lends itself to" validation at submission, but does not describe a deployment path that does not require Aries Systems (Editorial Manager's vendor) to ship a new feature. A more credible recommendation would be one of: (a) a journal-side "AI Disclosure 2.0" PDF attachment uploaded alongside the Cover Letter, validated by the editorial assistant against the linked Zenodo DOI; (b) a Crossref-style metadata extension that the journal opts into and that Editorial Manager treats as a free-text field with a URL pattern; or (c) a 90-day pilot at one Lancet group journal in which 5-10 submissions volunteer to attach the manifest and the editorial office reports back on whether it changed triage time. The Viewpoint will be much more publishable if Section 6 names one or two specific, concrete pilots (or names one Editorial Manager configuration option the journal could enable now) rather than asserting the manifest "is adoptable."

### Comment 4 — `high` — Equity dimension is absent

A Lancet Digital Health editor will ask, at desk triage: what does Disclosure 2.0 demand of a submitter who has no GitHub account, no Zenodo account, no continuous-integration budget, and no fluency in git history hygiene? The Viewpoint is silent on this. Two specific equity objections will be raised.

**4a. The proposal asymmetrically rewards well-resourced submitters.** A clinician-investigator in a setting without git infrastructure, or whose institutional IT does not permit code repositories on github.com, cannot meet the six-item manifest at all. Under the current policy, that submitter is allowed to submit (with the standard acknowledgement). Under Disclosure 2.0 as written, the submitter is locked out unless the manifest is optional — in which case its adoption is meaningless. The Viewpoint does not say how to resolve this.

**4b. The compliance burden is non-trivial for low-resource settings.** The case study in this repository took several weeks of expert-operator time, a paid Anthropic Claude subscription, and substantial local compute. The Viewpoint implicitly assumes any clinician-investigator can produce the manifest "on commodity tooling"; for the modal clinician-investigator at a non-academic centre in a low- or middle-income country, this is false. The Viewpoint either needs an equity carve-out (a tiered manifest, a minimum-viable manifest, a journal-hosted compute option, or an exception path) or needs to acknowledge that Disclosure 2.0 is a standard for a specific class of submission and not for all.

The author has the standing to make either argument (the case-study repository is large but assembled from genuinely free or near-free tools, except for the LLM subscription). What the Viewpoint cannot do is leave the question unaddressed, because an editorial board reviewing a policy proposal for a global journal will not.

### Comment 5 — `high` — Self-undermining demonstration claim about reviewer fabrication

Section 5 of the Viewpoint cites `reviewer-logs/round-01/methods.md` as evidence of a hallucinated citation that was preserved rather than silently deleted. I verified the artefact: `reviewer-logs/round-01/` exists as a directory but is currently **empty** as of the manuscript commit hash above. The cited fabrication-and-resolution exists in the manuscript's narrative but not in the repository the Viewpoint links to.

This is the most damaging single artefact-drift in the submission. The Viewpoint's strongest move is "we are produced under the standard"; a reader who clicks through to verify the cited round-01 evidence finds nothing. An editor will treat this as either (a) the operator over-stating what the demonstration shows, or (b) the demonstration not actually being complete at submission time. Either reading is fatal to the central rhetorical move.

The fix is one of: (i) populate the round-01 reviewer logs with the actual transcripts before submission and update the manuscript to reference the specific commit; (ii) remove the claim and replace it with a more general statement that *if* such a fabrication occurs, the standard preserves it; or (iii) move this Viewpoint to a submission window after the case-study reviewer rounds have actually run, so the claim is empirically true at submission. Option (iii) is the most honest and aligns with the operator's stated honesty contract in `docs/design.md`.

### Comment 6 — `medium` — Authorship-and-accountability framing is correct but undersold

Section 2 of the Viewpoint correctly notes that Disclosure 2.0 does not contest the ICMJE authorship exclusion for AI tools, and the Acknowledgements paragraph and Contributors section reinforce this. The framing is consistent and the proposed manifest does not weaken the exclusion at any point I could detect. This is a strength of the manuscript and the reviewer flags it positively.

The undersold dimension is that *making the manifest visible* is in fact the strongest possible reinforcement of the ICMJE authorship-exclusion — a reader who sees a six-item manifest disclosing every prompt and every tool envelope can verify, in a way the current acknowledgement paragraph does not permit, that the named human author actually retained accountability. The manuscript could state this explicitly (it almost does, in the closing paragraph of Section 3) and pre-empt the objection that Disclosure 2.0 is a path toward AI authorship. One sentence in Section 2 or Section 6 would suffice.

### Comment 7 — `medium` — The "audit log" item conflates two distinct functions

Disclosure 2.0 item 5 (Section 3) is **the audit log**, defined as a sealed subagent that re-executes the analysis, verifies citations against Crossref/PubMed, and re-derives headline statistics. The manuscript treats this as one item. In practice it is three different operations with different reliability profiles and different policy implications:

- **Re-execution.** A bit-level or distributional reproduction of the analysis. Verifiable.
- **Citation verification.** A claim-by-claim resolution against an external metadata source. Verifiable.
- **Headline-statistic rederivation.** Same as re-execution if Layer 1 was deterministic; different if Layer 1 involved LLM-mediated claim selection that is not bit-deterministic.

Conflating these in a single manifest item lets a future submitter discharge one of the three (the easy one) and claim discharge of all. Section 3 should either (i) split item 5 into three distinct sub-items in the manifest, or (ii) explicitly state that the audit log includes all three operations and that each must be present for compliance. The current wording will not survive the first round of editorial board review at any Lancet group journal.

### Comment 8 — `medium` — Reference list contains placeholder and unverifiable entries

`references.bib` is a Vancouver-style list of twelve entries with internal verification comments. Three entries are not currently verifiable at the level a Lancet group editorial board expects.

- `linehs2024` (Lin et al., *Journal of Cancer Research and Practice*): "Full author list and volume/issue to be verified against the journal record at submission." The author cannot submit a Viewpoint that cites their own prior work without a complete reference.
- `lintom2026` (Lin, arXiv preprint on theory-of-mind-like behaviour): "Precise arXiv eprint id to be inserted at submission; if the preprint is not yet posted to arXiv, this entry is removed." This is a placeholder, not a citation.
- `repoprereg` (preregistration, GitHub commit `<<PREREG_COMMIT_SHA>>`): the SHA is not filled. The Viewpoint's preregistration-driven Layer-3 argument loses its anchor.
- The headline of Section 4 contains the unresolved macro `<<HEADLINE:layer3_primary>>`.

The Viewpoint cannot go out for review with three placeholders in the reference list and one in the body. This is editorial-policy-adjacent rather than editorial-policy proper, but the policy reviewer flags it because it co-occurs with the larger artefact-drift issue.

### Comment 9 — `medium` — The "current Lancet policy classifies it as prohibited" framing is sharper than necessary

Section 1 closes: "Read literally, the policy classifies almost every action the workflow above performs as prohibited. Read sympathetically, the policy is protecting against three real harms…" This is a load-bearing rhetorical move and it works, but it leaves the door open for a desk editor to write "we read our own policy sympathetically; the manuscript is therefore arguing against a strawman." Suggested revision (suggestion-text, not direct edit): name the three specific permitted-use cases (language editing, grammar, prose) and the three specific harms the prohibited-use list targets, and concede that the policy's intent is sound while arguing its mechanism is mis-calibrated for 2026. This pre-empts the "you are misreading our policy" objection without losing the argument's force.

### Comment 10 — `low` — Cite the AMEE Guide and one cross-journal comparator

The Viewpoint is currently silent on the AMEE Guide No.192 (the most current pedagogical synthesis of journal AI policies, published 2025) and on the cross-journal comparisons (NEJM, Nature, JAMA, BMJ) that an editorial reviewer expects in a piece arguing for policy reform. One sentence acknowledging that the Lancet group's policy is consistent with the ICMJE recommendations and that the proposed Disclosure 2.0 is compatible with NEJM 2024, Nature Portfolio 2024 (with adjustments) and JAMA Network 2024 would broaden the audience for the Viewpoint and reduce the risk of being read as Lancet-specific advocacy.

### Comment 11 — `low` — The "operator-sovereign autonomy vs copilot-supervised" framing is welcome but the citation is fragile

Section 5 introduces "operator-sovereign autonomy" and "copilot-supervised" as two legitimate equilibria, citing the Academic Research Skills toolkit (`ars2026`) as a contemporaneous example of the copilot school. This is a strong move and the comparator citation is well-chosen. The fragility is that the citation is a GitHub release (CC BY-NC, 15,704 stars as of 2026-05-20) rather than a peer-reviewed source, which makes it a slightly soft anchor for a piece arguing about peer-reviewed publishing. The reviewer does not ask the operator to remove the citation — the comparator is good — but suggests adding a peer-reviewed reference on human-in-the-loop AI for scientific writing as a companion citation.

### Comment 12 — `low` — The "distributional reproducibility" definition needs a one-line operationalisation

Section 5 commits Disclosure 2.0 to "distributional reproducibility: the substantive findings reproduce when the same prompt is run against the same model id, on the same snapshot date, with the same tool envelope." The repository includes `case-study/analysis/99_reexec_check.py` which "runs Layer 1 three times and reports concordance on selected claim, statistical method, and headline effect size." One additional sentence in Section 5 specifying the *concordance threshold* (e.g. "the selected claim and statistical method must match across all three runs; the headline effect size must agree within bootstrap-95% overlap") would make the definition operational. As written, "distributional reproducibility" is a phrase, not a metric.

---

## Three editorial objections the operator should pre-empt in revision

These are the three objections I expect a Lancet group editorial board to raise at desk triage. They map to comments 1, 4, and 5 above.

1. **"You misquote our policy."** Comment 1. Lancet group editors will read the prohibited-uses sentence first and notice that the Viewpoint's paraphrase is not the policy's wording. Pre-empt by quoting the live page verbatim with a retrieval date, separating image generation into its own bullet, and clarifying the "one-place vs two-place" disclosure-location rule.

2. **"Disclosure 2.0 is for well-resourced submitters only."** Comment 4. Editors of a global health journal cannot endorse a standard whose deployment burden is plausibly concentrated in high-resource settings. Pre-empt by adding an explicit equity paragraph (one half-column) that (a) names the burden, (b) names a tiered or minimum-viable manifest, and (c) commits the operator's GitHub repository as a worked example available for any submitter to fork.

3. **"Your strongest evidence is a missing file."** Comment 5. The reviewer-fabrication claim in Section 5 references an empty repository directory. Editors will check this. Pre-empt by either populating `reviewer-logs/round-01/` with the actual transcripts before submission, or removing the specific cited claim and rephrasing as a class-level statement about what the standard preserves.

---

## Verdict

**`major-revision`.**

The Viewpoint is a publishable piece in some form; the central argument is original and the demonstration-by-self-instantiation is unusually powerful. The blocker (policy mis-quotation) and the two highest high-severity comments (symmetry-argument under-specification; missing reviewer-log artefact) require a focused revision before the next round. If those three are addressed, and the equity comment receives an explicit half-column response, the next round's verdict can plausibly be `minor-revision`.

A reviewer who endorses Disclosure 2.0 cannot endorse a Viewpoint about Disclosure 2.0 that contains artefact-drift relative to its own repository. The honesty contract in `docs/design.md` is the standard the manuscript must meet, not just the standard it proposes.
